US biotech takes the rights in kidney diseases collaboration

Japanese drugmaker Teijin Pharma (TYO: 3401) has granted the US biotech major Amgen (Nasdaq: AMGN) an exclusive license to compounds discovered or developed during a newly-announced collaborative research in nephrology.

The license to develop and commercialize the therapeutic agents for kidney diseases and disorders resulting from the collaboration covers everywhere in the world outside Japan. Teijin will also have the right to co-promote potential products in select Asian markets.

Teijin, which will receive an undisclosed upfront payment in addition to potential milestones and royalties, sees nephrology as an area of significant unmet need and is confident that the collaboration will yield new treatment options.